Chronic diseases and conditions are on the rise worldwide. An ageing population and changes in societal behavior are contributing to a steady increase in these common and long-term health problems. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% by the year 2020. Emerging markets like India will be hardest hit, as population growth is anticipated be most significant in developing nations. Increased demand on healthcare systems due to chronic disease has become a major concern.

With the exponential rise in population and increase in life expectancy, the chronic disease ailments like Diabetes, Hypertension, Arthritis, Gastro, Neurological and psychiatry illnesses tent to rise substantially in the coming decades. Already there is huge demand for providing required health care facilities and varieties of drugs to treat chronic disease ailments in neurology, psychiatry, orthopaedics, Gastroenterology and other chronic therapy areas.

There will likely be explosive growth in potential medical therapies including novel drugs in the above fields of medicine.

Starus pharma group realized this need at the time of inception itself and entered into chronic disease management areas by launching its flagship division Starus Division to focus on chronic therapy areas, working on innovation and offered several new to India products in chronic therapy areas. Starus division promises medical fraternity to continuously work with them and provide novel therapeutic solutions from time to time. Starus division is fortunate to be taken care directly by Chaiman and M.D Dr P Uday Kiran with special care and attention.